IP Library › Granted Patent US 11,938,123
Granted Patent B2
US 11,938,123 · App. 17/059,046 · Granted Mar 26, 2024

Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancers

Inventors: Jeong Hyeok Yoon (Yongin-Si, KR); Ky Youb Nam (Goyang-Si, KR)
Assignee: PHAROS IBIO CO., LTD.
A61K31/4535A23L33/10A61K45/06A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,938,123
App. No.
17/059,046
Granted
Mar 26, 2024
Kind
B2
Abstract

A composition for preventing, ameliorating or treating breast cancer, the composition containing a 2,3,5-substituted thiophene compound according to one embodiment of the present disclosure has an excellent activity of inhibiting the proliferation of breast cancers, particularly triple-negative breast cancer and Herceptin-resistant breast cancer, which have high mortality because there has yet been no effective therapeutic method therefor. Thus, the composition may be advantageously used for the prevention, amelioration or treatment of breast cancer.

Claims (6)

1. A method for treating breast cancer, the method comprising a step of administering to a subject in need thereof pharmaceutical composition containing a compound represented by the following Formula 1 or a pharmaceutically acceptable salt thereof,

wherein the breast cancer is triple-negative breast cancer or Herceptin-resistant breast cancer:

2. The method of claim 1 , wherein the pharmaceutical composition further contains cisplatin.

3. The method of claim 1 , wherein the pharmaceutical composition further contains a poly(ADP-ribose) polymerase (PARP) inhibitor.

4. The method of claim 3 , wherein the PARP inhibitor is one or more anticancer drugs selected from the group consisting of olaparib, rucaparib, talazoparib and veliparib.

5. The method of claim 1 , wherein the pharmaceutically acceptable salt is a hydrochloride salt.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2021
From: YOON, JEONG HYEOK; NAM, KY YOUB
To: PHAROS IBIO CO., LTD.
Reel/Frame 054978/0974 →
Priority Claims (1)
KR 10-2018-0061786 · May 30, 2018 · national
Continuity (1)
Related Publication 20210205290A1 · Jul 8, 2021
Cited By (1)
US 12,514,851